Tuberculin, 1890

A vial of Koch?s Tuburculin from 1895 resides at Charité Hospital, Berlin. Credit: Courtesy of Terry Sharrer" />A vial of Koch?s Tuburculin from 1895 resides at Charité Hospital, Berlin. Credit: Courtesy of Terry Sharrer Robert Koch (1843?1910), who isolated Mycobacterium tuberculosis in 1882 and proved that it caused tuberculosis, announced at a medical congress in Berlin eight years later that he had developed a substance capable of preventing the growth of the tub

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Robert Koch (1843?1910), who isolated Mycobacterium tuberculosis in 1882 and proved that it caused tuberculosis, announced at a medical congress in Berlin eight years later that he had developed a substance capable of preventing the growth of the tubercle bacilli, thus arresting the disease. He called this substance ?tuberculin,? while keeping its formulary secret. Actually, it was a glycerin-broth culture he used to grow M. tuberculosis, which he then evaporated to one-tenth its volume at 100° C before filtering. Within days, newspapers around the world announced that Koch had a cure for tuberculosis.

The truth surfaced months later. Tuberculin did not cure tuberculosis, and actually harmed patients who had the advanced disease. When Rudolf Virchow published negative findings about tuberculin in January 1891, Koch felt pressured to reveal its simple preparation. Adulation descended to ridicule, when, besides disappointment over tuberculin, the public learned that the 50-year old Koch was divorcing ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Terry Sharrer

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

fujirebio-square-logo

Fujirebio Receives Marketing Clearance for Lumipulse® G pTau 217/ β-Amyloid 1-42 Plasma Ratio In-Vitro Diagnostic Test

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours